The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 765K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

25 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
104
Antitumor agents. 199. Three-dimensional quantitative structure-activity relationship study of the colchicine binding site ligands using comparative molecular field analysis.EBI
University of North Carolina at Chapel Hill
39
A quantitative analysis of kinase inhibitor selectivity.EBI
Ambit Biosciences
2
Synthesis and antiproliferative activity of a cyclic analog of dolastatin 10.EBI
Laboratoire Des M£Canismes Mol£Culaires Des Communications Cellulaires (Cnrs Upr 9023)
8
 
Design and synthesis of curacin a analogs with varied side chain structuresEBI
TBA
2
 
Centaureidin, a cytotoxic flavone from Polymnia fruticosa, inhibits tubulin polymerizationEBI
TBA
3
 
Synthesis and biological properties of 1069C: a new synthetic antitumour agent with very low cross-resistance potentialEBI
TBA
18
 
Synthesis and nti-tubulin activity of aza-combretastatinsEBI
TBA
6
 
Structural requirements for the binding of colchicine analogs to tubulin: the role of the C-10 substituentEBI
TBA
2
Antimitotic activity of glaupalol-related coumarins from Glaucidium palmatum.EBI
Hokkaido University
7
Antitumor agents. Part 226: synthesis and cytotoxicity of 2-phenyl-4-quinolone acetic acids and their esters.EBI
University of North Carolina
11
The total synthesis of an aurone isolated from Uvaria hamiltonii: aurones and flavones as anticancer agents.EBI
Cardiff University
1
Synthesis and investigation of conformationally restricted analogues of lavendustin A as cytotoxic inhibitors of tubulin polymerization.EBI
Purdue University
1
Synthesis and biological evaluation of structurally highly modified analogues of the antimitotic natural product curacin A.EBI
University of Pittsburgh
16
Antitumor Agents. 211. Fluorinated 2-phenyl-4-quinolone derivatives as antimitotic antitumor agents.EBI
University of North Carolina
8
The synthesis and tubulin binding activity of thiophene-based analogues of combretastatin A-4.EBI
Australian National University
5
Novel sulfonate derivatives: potent antimitotic agents.EBI
Abbott Laboratories
9
Novel sulfonate analogues of combretastatin A-4: potent antimitotic agents.EBI
Abbott Laboratories
5
Antineoplastic agents. 443. Synthesis of the cancer cell growth inhibitor hydroxyphenstatin and its sodium diphosphate prodrug.EBI
Arizona State University
1
Synthesis and biological evaluation of dihydrobenzofuran lignans and related compounds as potential antitumor agents that inhibit tubulin polymerization.EBI
University of Antwerp
1
Potent antimitotic and cell growth inhibitory properties of substituted chalcones.EBI
University of Manchester Institute of Science and Technology
1
Synthesis and in vitro cancer cell growth inhibitory activity of monocyclic model compounds containing spongistatin triene side-chains.EBI
University of Pennsylvania
1
Antitumor agents. 166. Synthesis and biological evaluation of 5,6,7,8-substituted-2-phenylthiochromen-4-ones.EBI
University of North Carolina
17
Synthesis, tubulin binding, antineoplastic evaluation, and structure-activity relationship of oncodazole analogues.EBI
Smith Kline & French Laboratories
15
Therapeutic methods, combinations and kitsBDB
University of Minnesota
18
Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors.BDB
Astellas Pharma